Summary & Overview
CPT 80373: Tramadol Detection/Quantitation in Patient Specimen
CPT code 80373 represents a laboratory toxicology test that detects or measures tramadol, a centrally acting opioid analgesic, in patient specimens. Nationally, this code matters because tramadol screening and quantitation support clinical decision-making for pain management, patient safety, and medication monitoring amid ongoing attention to opioid use and misuse.
Key payers commonly involved in coverage considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Payment policies for tramadol testing vary across commercial and public payers and can influence laboratory utilization and clinical workflows.
Readers will find an overview of the clinical context for tramadol testing, typical sites of service, and the service type. The publication summarizes payer coverage patterns and benchmarks where available, highlights relevant coding and billing considerations tied to CPT code 80373, and outlines common modifiers used in laboratory billing. The content is intended to inform clinicians, laboratory managers, and billing professionals about the role of tramadol testing in clinical care and the key administrative considerations that affect reimbursement and documentation. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 80373 describes a laboratory test that measures the amount of, or detects the presence of, tramadol in a patient specimen. This test is a form of toxicology/therapeutic drug monitoring focused on a centrally acting opioid analgesic commonly prescribed for pain management.
-
Service type: Clinical laboratory toxicology assay for tramadol quantitation or detection
-
Typical site of service: Clinical laboratory, hospital laboratory, reference laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient on chronic pain management presents for an outpatient urine or serum drug test to confirm tramadol use and detect possible misuse or diversion. The clinician orders a targeted tramadol assay when the patient reports increased pain, requests dose escalation, or when pill count/observed behavior raises concern for nonadherence. A specimen (urine or blood) is collected in a clinic laboratory or sent to a reference lab. The laboratory analyst performs qualitative or quantitative testing to detect the presence of tramadol and/or its major metabolite(s). Results are reported to the ordering clinician and used to guide therapy decisions, verify adherence to a controlled-substance agreement, or support occupational or forensic testing. Typical site of service: outpatient clinic, hospital laboratory, or independent diagnostic laboratory. Service type: laboratory drug/toxicology test specific to tramadol detection/quantification using immunoassay and/or confirmatory methods such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography–tandem mass spectrometry (LC-MS/MS).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified service | When no modifier is required; standard reporting. |
26 |